Kantar Health Blog

  • Stephanie Hawthorne
    As treatment of lung cancer patients has become more driven by histology and biomarkers, one group of patients had been left out of the clinical advances made in recent years with targeted therapies: non-small cell lung cancer (NSCLC) patients whose tumors have squamous histology.
    Continue Reading > | Go comment! | Share
  • Yervoy paves the way in adjuvant melanoma

    by Stephanie Hawthorne | Jun 3, 2014
    Stephanie Hawthorne
    Yervoy® (ipilimumab, Bristol-Myers Squibb) was an exciting and welcomed breakthrough in the treatment of advanced/metastatic melanoma when it was first launched in 2011. The agent not only improved the median overall survival (OS) in patients irrespective of BRAF status; it also showed a plateau in the survival curve, indicating that a subset of patients derive long-term benefit from Yervoy. Given the poor prognosis of metastatic disease, however, could Yervoy have a greater impact on survival outcomes if used earlier in the course of the disease?
    Continue Reading > | Go comment! | Share
  • Neesha Suvarna
    Cyramza™ (ramucirumab, IMC-1121B; Eli Lilly) is a human IgG1 monoclonal antibody directed against the extracellular domain of VEGFR-2. It was recently approved by the Food and Drug Administration (FDA) for advanced gastric cancer or gastroesophageal junction adenocarcinoma. On February 19, 2014, Lilly announced via press release that the REVEL trial was positive for both overall survival (OS) and progression-free survival (PFS) benefit.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Both Avastin® (bevacizumab, Genentech/Roche/Chugai) and Erbitux® (cetuximab, Bristol -Myers Squibb/Eli Lilly/Merck KGaA) are approved for the treatment of first-line metastatic colorectal cancer (mCRC) and have demonstrated progression-free survival (PFS) and overall survival (OS) benefits when added to standard chemotherapy in these patients. As with all therapies that exist in the same indication, physicians are left wondering how best to incorporate these agents into their practices.
    Continue Reading > | Go comment! | Share
  • Neesha Suvarna
    The role of PD-1 in suppression of antitumor immunity was one of the hottest topics at the 2012 American Society of Clinical Oncology (ASCO) annual meeting. Excitement around this topic intensified at ASCO 2013, and the story continues to unfold in 2014.
    Continue Reading > | Go comment! | Share